|
|
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- NHS Trusts (England) - Chief Executive
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- Special Health Authorities
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- GP - Locum
- NHS 111 and Out of hours providers
- GP Practices
- Community Pharmacy
- Primary Care Networks
- GP Practices 1
|
Title: |
|
Withdrawal of the Recommendation for Consideration of Inhaled Budesonide as a Treatment Option for COVID-19
|
Broadcast content: |
|
In parallel to the publication of revised guidance from the National Institute for Health and Care Excellence (NICE), the previously published UK interim position statement covering inhaled budesonide as a treatment option for individuals with COVID infection has been withdrawn. Inhaled budesonide should no longer be considered as a treatment for COVID-19 infection other than within the context of a clinical trial. People already using budesonide for conditions other than COVID-19 should continue treatment if they test positive for COVID-19.
|
Additional information: |
|
NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy
|